一種新型系統(tǒng)被設(shè)計(jì)用于將內(nèi)科醫(yī)生專(zhuān)用藥物以及其它治療藥物直接給予腎功能不全患者的腎動(dòng)脈之中，這些患者將從靶向腎臟治療(TRT)中獲益，包括那些充血性心衰的患者。這套系統(tǒng)已經(jīng)獲得了美國(guó)食品藥品管理局的許可。

Benephit Delta系統(tǒng)是系統(tǒng)性靜脈灌注給藥系統(tǒng)標(biāo)準(zhǔn)給藥方法的替代選擇，用于治療腎功能不全相關(guān)的心血管疾病、腎功能衰竭、以及充血性心衰。這套系統(tǒng)的早期版本局限在介入實(shí)驗(yàn)室中應(yīng)用，將單個(gè)導(dǎo)管放入患者腹股溝股動(dòng)脈入口處，進(jìn)行介入手術(shù)進(jìn)行靶向腎臟治療。

Benephit Delta系統(tǒng)外觀簡(jiǎn)練、靈活性增加、長(zhǎng)度更長(zhǎng)，從而能夠進(jìn)入諸如上肢這樣的動(dòng)脈位點(diǎn)。系統(tǒng)設(shè)計(jì)當(dāng)患者接受治療的時(shí)候具有更大機(jī)動(dòng)性，當(dāng)離開(kāi)實(shí)驗(yàn)室的時(shí)候具有更好的舒適度。患者將從這種靶向腎臟治療方法中獲益，包括出現(xiàn)腎功能衰竭的慢性心衰患者以及急性腎功能衰竭患者。

Scripps診所心血管科介入心臟病學(xué)主任Paul Teirstein醫(yī)生評(píng)論說(shuō)：“除了心-腎綜合征的充血性心衰患者之外，Delta系統(tǒng)還能夠用于治療在重癥監(jiān)護(hù)室、手術(shù)中間或之后發(fā)生急性腎功能衰竭的患者。”

Benephit Delta系統(tǒng)是由FlowMedica公司研制開(kāi)發(fā)成功的。

Infusion System for Kidney Patients
 
A new system is designed for the administration of physician-specified medications and other therapeutic agents directly into the renal arteries of patients with kidney dysfunction who may benefit from targeted renal therapy (TRT), including those with congestive heart failure. The system has been cleared by the U.S. Food and Drug Administration (FDA).

The Benephit Delta system is an alternative to the standard delivery method of systemic intravenous (IV) infusion of medications to treat kidney dysfunction related to cardiovascular disease, kidney failure, and congestive heart failure (CHF). An earlier version of the system was limited to use in the interventional laboratory, where a single catheter is placed in a femoral artery access site in the patient’s groin enabling interventional procedures to take place concurrently with TRT.

The reduced profile, increased flexibility, and longer lengths of the Benephit Delta system allow for access through arterial sites such as the arm. The system is designed to allow greater patient mobility and ease in providing therapy once the patient leaves the interventional laboratory. Patients who may benefit from this approach to TRT include CHF patients who develop kidney dysfunction and patients with acute renal failure.

“In addition to congestive heart failure patients who develop cardiorenal syndrome, the Delta system might also be used to provide therapy to patients who develop acute kidney failure while in the intensive care unit, during or after surgery,” commented Paul Teirstein, M.D., director of interventional cardiology, Division of Cardiovascular Diseases, Scripps Clinic (La Jolla, CA, USA).

The Benephit Delta system was developed by FlowMedica (Fremont, CA, USA).